Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC

Introduction: Durvalumab maintenance therapy after definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III NSCLC. Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of subsequent durvalumab therapy, data on the effect of TRL...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	JTO Clinical and Research Reports
المؤلفون الرئيسيون:	Tomoki Kuge, MD, Takayuki Shiroyama, MD, PhD, Akihiro Tamiya, MD, Motohiro Tamiya, MD, Masaki Kanazu, MD, Yuhei Kinehara, MD, PhD, Tsunehiro Tanaka, MD, Osamu Morimura, MD, PhD, Yoshihiko Taniguchi, MD, Toshie Niki, MD, PhD, Satoshi Tetsumoto, MD, PhD, Kazuhiko Hayashi, MD, PhD, Kazumi Nishino, MD, PhD, Izumi Nagatomo, MD, PhD, Atsushi Kumanogoh, MD, PhD
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2023-05-01
الموضوعات:	Chemoradiation Durvalumab Lymphocyte Count Stage III Treatment-related lymphopenia
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2666364323000449